Stanford Degraffenreaid v. Ceva Logistics U.S., Inc., et al.

CourtDistrict Court, S.D. Texas
DecidedMarch 30, 2026
Docket4:23-cv-04230
StatusUnknown

This text of Stanford Degraffenreaid v. Ceva Logistics U.S., Inc., et al. (Stanford Degraffenreaid v. Ceva Logistics U.S., Inc., et al.) is published on Counsel Stack Legal Research, covering District Court, S.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Stanford Degraffenreaid v. Ceva Logistics U.S., Inc., et al., (S.D. Tex. 2026).

Opinion

Southern District of Texas ENTERED March 30, 2026 UNITED STATES DISTRICT COURT Nathan Ochsner, Clerk SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION

STANFORD DEGRAFFENREAID, § § Plaintiff, § § VS. § CIVIL ACTION NO. 4:23-CV-04230 § CEVA LOGISTICS U.S., INC., et al., § § Defendants. § ORDER Pending before the Court is a Motion for Summary Judgment filed by Defendants CEVA Logistics, U.S., Inc. and CEVA Ground, U.S., LP Gointly, “CEVA” or “Defendants”). (Doc. No. 16). Plaintiff Stanford Degraffenreaid (“Degraffenreaid” or “Plaintiff’) filed a response, (Doc. No. 17), and Defendants replied, (Doc. No. 18). Having reviewed these documents, the record, and the applicable law, the Court hereby GRANTS Defendants’ Motion for Summary Judgment. (Doc. No. 16). BACKGROUND This is a disability discrimination case. Degraffenreaid began working at CEVA in 2010 as a Fleet Manager and was promoted to Fleet Operations Manager by 2012. (Doc. No. 16-1 at 46:17, 57:5-9) (Deposition Transcript of Stanford Gegraffenreaid). As the Fleet Operations Manager, Degraffenreaid worked onsite, along with his subordinates, supervising up to 15 employees and helping to handle escalated issues. (/d. at 92:24—-93:10); (Doc. No. 17-2 at 2) (Stanford Degraffenreaid’s Declaration).

In November 2013, Degraffenreaid was diagnosed with chronic kidney disease. (Doc. No. 17-2 at 2); (Doc. No. 16-1 at 264:22—24). As a result, he sought regular care from his physician and nephrologist. (Doc. No. 16-1 at 265:24-266:6). Between 2013 and 2020, Degraffenreaid’s doctors monitored his condition through bloodwork completed every four to six months. (/d. at 270:5—15). Degraffenreaid was not on any medication for his condition and did not receive any dialysis treatments during this time. See (id.). In March 2020, the COVID-19 pandemic hit the United States. Since CEVA was an essential business, it remained operational during the pandemic and Degraffenreaid was still required to be in the office. (Ud. at 95:4-96:21). While CEVA implemented safety procedures to minimize employees’ exposure to COVID-19, Degraffenreaid testified that he felt these procedures were not being followed or taken seriously. id at 199:1-202:24). Nevertheless, Degraffenreaid continued to work at CEVA for the first five months of the pandemic. He testified that he never tested positive for COVID-19, nor did any of the employees he supervised. (/d. at 122:1—11; 202:25-203:9). On July 28, 2020, Degraffenreaid received blood test results indicating that his Glomerular Filtration Rate (“GFR”) had “plummeted” to below 10. (/d. at 157:7-14); (Doc. No. 17-2 at § 6).! Degraffenreaid testified that, at this stage, “dialysis would have been recommended” but he did not have insurance to cover it. (Doc. No. 16-1 at 246:20—25). That same day, Degraffenreaid told his supervisor, Jonathan Lovelace, that he had a “health issue” that put him at risk of COVID-19 and he needed to “do something safe and stay home until [he] figure[d] out [what was] going on.”

' Plaintiff avers in his declaration that, prior to July 28, 2020, his GFR was consistently between 15-19, meaning he had Stage 4 chronic kidney disease. (Doc. No. 17-2 at 6). When his GFR dropped below 15 in July 2020, he was considered to have Stage 5 chronic kidney disease or End Stage Renal Disease (“ESRD”). Ud. at 4] 5—6). For the sake of this order, the Court refers to Plaintiff’s condition as “chronic kidney disease” since that description applies during the entirety of the relevant timeline.

(d. at 160:1—10, 160:22—161:5). Degraffenreaid told Lovelace he was going to need to “take some PTO.” (/d. at 160:9-10). Degraffenreaid did not report to work the next day, July 29, 2020. (/d. at 250:4-7). A few days later, Degraffenreaid checked in with Lovelace again, informing him that he was trying to find a new physician and specialist. (/d. at 162:21-164:15). Degraffenreaid then accessed The Hartford portal, the third-party Family and Medical Leave Act (“FMLA”) and disability administrator used by CEVA. (/d. at 176:23-177:1; 178:3- 179:3). Degraffenreaid applied for FMLA and short-term disability benefits through The Hartford. (/d. at 179:25—180:8). Around August 3, 2020, Degraffenreaid received a letter from The Hartford stating that he was eligible for FMLA leave and a determination on his short term benefits was pending. (/d. at 187:19-189:1); (Doc. No. 16-3 at 1) (August 3, 2020 Letter). The letter specifically provided that once The Hartford received “the necessary information” from Degraffenreaid’s health care provider to support his leave request, due by August 20, 2020, they would make a determination regarding his request for short term benefits. (Doc. No. 16-1 at 189:1—7). On August 4, 2020, Degraffenreaid emailed Lovelace an update, stating that he was “awaiting an appointment with a [s]pecialist to determine [his] next course of action” and he “would like to continue to take PTO to ensure [he] stay[s| safe” and “protect [his] physical health from COVID-19 risks.” (Ud. at 197:14—-198:15); (Doc. No. 16-4 at 3). Degraffenreaid then received another letter from The Hartford stating that his short term benefit claim had been denied and that, if he wished to pursue leave under the FMLA, his health care provider needed to complete the Certificate of Health Care Provider form by August 25, 2020. (Doc. No. 16-3 at 2). At the same time, Degraffenreaid was still trying to make an appointment with a specialist. He emailed Lovelace on August 11, 2020, stating that he had confirmed an appointment with a specialist for August 31, 2020, but was working to try to find an earlier appointment. See (Doc.

No. 16-4 at 1). Degraffenreaid ultimately confirmed with Lovelace on August 12, 2020, that he was unable to secure an earlier appointment. (/d.). Around August 14, 2020, Degraffenreaid received another letter from The Hartford stating that they had not received the supporting documentation they previously requested and again requested that Degraffenreaid have his health care provider complete a Certificate of Health Care Provider form to support his FMLA request. (/d. at 192:8-20) (Doc. No. 16-3 at 3) (August 14, 2020 Letter). Degraffenreaid admitted that it was his understanding that The Hartford required information from his health care provider, but he did not recall the details of whether he or his doctor had submitted the requested information. (Doc. No. 16-1 at 189:8—191:5). On August 19, 2020, The Hartford sent Degraffenreaid a letter denying his requests for FMLA leave and short term benefits. (Doc. No. 16-3 at 5). In light of Degraffenreaid’s requests being denied, CEVA sent a letter to Degraffenreaid on August 21, 2020, informing him that his continued absences would be considered unexcused if he did not provide a physician’s note supporting his time away by August 25, 2020. (Doc. No. 16- 5) (August 21, 2020 CEVA Letter). The letter noted that without a doctor’s note, CEVA expected Degraffenreaid to return to work immediately. (/d.). On August 25, 2020, Degraffenreaid sent an email to Lovelace and Kendace Culbreth, an employee in human resources at CEVA, attaching a letter from Dr. Bazgha Khalid, a doctor at Kesley-Seybold Clinic, stating that Degraffenreaid was a patient in his medical practice and “[b]ased on guidelines regarding COVID-19 disease, he [was] at a higher than average risk for complications than the general population.” (Doc. No. 16-7 at 3). Degraffenreaid testified that Dr. Khalid did not tell him he was unable to work and no doctor told him he could not work, or should not go into work. (Doc. No. 16-1 at 210:12—-15, 251:21-25, 273:25-274:4, 276:16—20,278:7—-9,279:25—280:2).

On August 26, 2020, Culbreth emailed Lovelace asking if Degraffenreaid had provided any additional medical documentation. See (Doc. No. 17-11 at 2). Lovelace reported that he had not received anything. (/d.).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Loulseged v. Akzo Nobel Inc.
178 F.3d 731 (Fifth Circuit, 1999)
Seaman v. C S P H Inc
179 F.3d 297 (Fifth Circuit, 1999)
Malacara v. Garber
353 F.3d 393 (Fifth Circuit, 2003)
Pegram v. Honeywell, Inc.
361 F.3d 272 (Fifth Circuit, 2004)
Rodriguez v. Conagra Grocery Prod
436 F.3d 468 (Fifth Circuit, 2006)
Triple Tee Golf, Inc. v. Nike, Inc.
485 F.3d 253 (Fifth Circuit, 2007)
Powers v. Woodlands Religious Community Inc.
323 F. App'x 300 (Fifth Circuit, 2009)
McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Jack Bell v. Dallas Cty Dept Hlth Human Svc
432 F. App'x 330 (Fifth Circuit, 2011)
Griffin v. United Parcel Service, Inc.
661 F.3d 216 (Fifth Circuit, 2011)
John Gober v. Frankel Family Trust
537 F. App'x 518 (Fifth Circuit, 2013)
NME Hospitals, Inc. v. Rennels
994 S.W.2d 142 (Texas Supreme Court, 1999)
Jeffrey Neely v. PSEG Texas Limited Partnership, e
735 F.3d 242 (Fifth Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Stanford Degraffenreaid v. Ceva Logistics U.S., Inc., et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/stanford-degraffenreaid-v-ceva-logistics-us-inc-et-al-txsd-2026.